Achilles Therapeutics Pl-adr (ACHL)

$1.05

Market is closed - opens 8 PM, 08 Nov 2024

Performance

  • $1.03
    $1.07
    $1.05
    downward going graph

    1.9%

    Downside

    Day's Volatility :3.74%

    Upside

    1.87%

    downward going graph
  • $0.63
    $1.76
    $1.05
    downward going graph

    40.0%

    Downside

    52 Weeks Volatility :64.2%

    Upside

    40.34%

    downward going graph

Returns

PeriodAchilles Therapeutics Pl-adrSector (Health Care)Index (Russel 2000)
3 Months
36.6%
1.4%
0.0%
6 Months
26.51%
3.8%
0.0%
1 Year
26.44%
15.3%
0.0%
3 Years
-84.77%
11.4%
-27.4%

Highlights

Market Capitalization
44.2M
Book Value
$2.81
Earnings Per Share (EPS)
-1.59
Wall Street Target Price
2.83
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-26.82%
Return On Equity TTM
-44.22%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-65.9M
Diluted Eps TTM
-1.59
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.57
EPS Estimate Next Year
-1.87
EPS Estimate Current Quarter
-0.41
EPS Estimate Next Quarter
-0.43

Analyst Recommendation

Buy
    70%Buy
    20%Hold
    10%Sell
Based on 10 Wall street analysts offering stock ratings for Achilles Therapeutics Pl-adr(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
8
Hold
2
1
1
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 169.52%

Current $1.05
Target $2.83

Technicals Summary

Sell

Neutral

Buy

Achilles Therapeutics Pl-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Achilles Therapeutics Pl-adr
Achilles Therapeutics Pl-adr
3.47%
26.51%
26.44%
-84.77%
-85.3%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Achilles Therapeutics Pl-adr
Achilles Therapeutics Pl-adr
0.17
NA
NA
-1.57
-0.44
-0.27
NA
2.81
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Achilles Therapeutics Pl-adr
Achilles Therapeutics Pl-adr
Buy
$43.8M
-85.3%
0.17
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Achilles Therapeutics Pl-adr

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.4% return, outperforming this stock by 34.0%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 130.6%

Institutional Holdings

  • Syncona Portfolio Ltd.

    26.98%
  • FCPM III SERVICES BV

    5.82%
  • Redmile Group, LLC

    3.91%
  • Vestal Point Capital LP

    3.65%
  • Ikarian Capital, LLC

    3.51%
  • Baker Bros Advisors LP

    2.70%

Company Information

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Organization
Achilles Therapeutics Pl-adr
Employees
204
CEO
Dr. Iraj Ali Ph.D.
Industry
Healthcare

FAQs